 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...456457458459460461462463464465466...522523» |
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, P2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (Pubmed Central) - Jan 1, 2019
P2
In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases.
- | Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Clinical, P2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. (Pubmed Central) - Jan 1, 2019
P2
This regimen could represent a new standard of care for this population. A randomised, phase 3 study to evaluate the efficacy of this combination compared with chemotherapy plus earlier-generation tyrosine-kinase inhibitors is warranted.
- ||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (clinicaltrials.gov) - Dec 26, 2018
P2, N=200, Recruiting, Sponsor: St. Jude Children's Research Hospital
A randomised, phase 3 study to evaluate the efficacy of this combination compared with chemotherapy plus earlier-generation tyrosine-kinase inhibitors is warranted. N=125 --> 200
- | fluorouracil topical / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma. (Pubmed Central) - Dec 26, 2018
N=125 --> 200 From our data we conclude that an ACF-induced increase in EpCAM expression reflects the selection of a CSC subpopulation that underlies tumor development and drug resistance in EAC.
- | Leukine (sargramostim) / Partner Therap, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
New P2 trial: NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Dec 26, 2018
P2, N=45, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | dacarbazine / Generic mfg., doxorubicin hydrochloride / Generic mfg., vincristine / Generic mfg.
Clinical, Journal: Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy. (Pubmed Central) - Dec 24, 2018
One patient had an out-of-field relapse, yielding a 4-year relapse-free survival rate of 92.9% (95%CI [59.1, 99.0]). Our results showed that with careful patient selection by initial disease characteristics and FDG-PET response to chemotherapy, the use of a more restricted treatment volume of ISRT to 20 Gy following ABVD × 2 is associated with excellent outcomes.
- | Revlimid (lenalidomide) / BMS, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal, HEOR: Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. (Pubmed Central) - Dec 24, 2018
The subtype-based approach showed a favorable incremental cost-effectiveness ratio of $15,015/quality-adjusted life year compared with RCHOP. Although our exploratory analyses demonstrated a wide range of conditions where subtype-based treatment remained cost-effective, data from phase 3 trials are needed to validate our models' findings and draw definitive conclusions.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
New P3 trial, PD(L)-1 Biomarker, Metastases: APTneo: Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 22, 2018
P3, N=650, Not yet recruiting, Sponsor: Fondazione Michelangelo
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Review, Journal: Update on the Treatment of Anaplastic Large Cell Lymphoma. (Pubmed Central) - Dec 22, 2018
A randomized phase III study is ongoing comparing brentuximab plus CHP (cyclophosphamide, doxorubicin, prednisone) with standard CHOP in the front-line setting. The use of targeted therapies and other novel agents have improved outcomes for ALCL patients and in the future can complement or even replace the current standard of care and front-line treatment options.
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date: Myocardial Perfusion and Fibrosis in Cancer Survivors (clinicaltrials.gov) - Dec 21, 2018
P=N/A, N=16, Recruiting, Sponsor: Wake Forest University Health Sciences
The use of targeted therapies and other novel agents have improved outcomes for ALCL patients and in the future can complement or even replace the current standard of care and front-line treatment options. Trial completion date: Mar 2019 --> Dec 2018
- |||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P2 trial, Combination therapy: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/ taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency) (EUDRACT) - Dec 20, 2018
P2, N=90, Ongoing, Sponsor: Austrian Breast & Colorectal Cancer Study Group (ABCSG)
- |||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Combination therapy, PD(L)-1 Biomarker, IO biomarker: IMpassion050: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (clinicaltrials.gov) - Dec 20, 2018
P3, N=224, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2019 --> Dec 2018 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Combination therapy: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) (clinicaltrials.gov) - Dec 20, 2018
P3, N=1140, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Tecentriq (atezolizumab) / Roche
Enrollment closed, Combination therapy: IMpassion031: A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 19, 2018
P3, N=204, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy: NEMIO: NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (clinicaltrials.gov) - Dec 19, 2018
P1/2, N=120, Recruiting, Sponsor: Association Pour La Recherche des Th
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Xpovio (selinexor) / Karyopharm
Enrollment change, Combination therapy, IO biomarker, Metastases: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 17, 2018
P1, N=247, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=588 --> 247
- | doxorubicin hydrochloride / Generic mfg.
Journal: Zwitterionic Temperature/Redox-Sensitive Nanogels for Near-Infrared Light-Triggered Synergistic Thermo-chemotherapy. (Pubmed Central) - Dec 16, 2018
Here, we develop zwitterionic temperature/redox-sensitive nanogels loaded with near-infrared (NIR) dye Indocyanine green (ICG) and anticancer drug doxorubicin (I/D@NG)...This nanoplatform for thermo-chemotherapy not only efficiently exerts synergistic cytotoxicity, but also overcomes all the physiological barriers of therapeutic agent, thereby providing substantial in vivo anticancer effect. The multiple functions of I/D@NG provide new insights into designing nanoplatforms for synergistic cancer therapy.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Anticancer activity of 2'-hydroxyflavanone towards lung cancer. (Pubmed Central) - Dec 15, 2018
Additionally, 2HF inhibited efflux of doxorubicin and increased its accumulation in the cells, but did not add to the transport inhibitory effect of anti-Rlip antibodies alone...Our result suggest that Rlip inhibition is likely a mechanism of action. Our findings are basis of proposing 2HF as therapeutic or preventative drug for lung cancer.
- | Roferon A (recombinant interferon alfa-2a) / Roche
Retrospective data, Review, Journal: Intravesical Therapy for the Treatment of Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. (Pubmed Central) - Dec 14, 2018
For NMIBC, several intravesical therapies are associated with decreased risk of bladder cancer recurrence versus TURBT alone. BCG is the only agent associated with decreased progression risk versus TURBT alone, but may be associated with higher risk of adverse events than other intravesical therapies, indicating trade-offs between potential benefits and harms.
- | ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Biomarker, Clinical, Review, Journal: Uterine Leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. (Pubmed Central) - Dec 14, 2018
Cytotoxic chemotherapy remains the mainstay of therapy for advanced-stage, recurrent, or metastatic LMS, and includes single or combination doxorubicin-, ifosfamide-, or gemcitabine-based regimens. Recent interest in genetic biomarkers led to developments of targeted therapies for LMS, although more research is needed to understand the molecular complexities underlying LMS to guide the development of novel treatment strategies.
- | doxorubicin hydrochloride / Generic mfg.
Journal: HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. (Pubmed Central) - Dec 14, 2018
Overall, our novel mechanistic and preclinical studies together demonstrate that HDAC1,2 selective inhibition can overcome DSB repair 'addiction' and provide an effective therapeutic option for Ph+ B-cell precursor ALL.Leukemia accepted article preview online, 05 June 2017. doi:10.1038/leu.2017.174.
- | Clinical, Journal: Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. (Pubmed Central) - Dec 14, 2018
For those patients that were cT0 after NAC and refused or were ineligible for RC, 5-year disease-free survival was nearly 60% and cancer-specific survival was nearly 90%. Future studies should focus on identifying clinical and molecular factors associated with a durable pathologic complete response after NAC.
- | topotecan / Generic mfg., cyclophosphamide / Generic mfg., vincristine / Generic mfg.
Trial primary completion date, Metastases: AEWS1031: Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma (clinicaltrials.gov) - Dec 14, 2018
P3, N=693, Active, not recruiting, Sponsor: Children's Oncology Group
Future studies should focus on identifying clinical and molecular factors associated with a durable pathologic complete response after NAC. Trial primary completion date: Dec 2019 --> Mar 2020
- | Oncaspar liquid (pegaspargase) / Servier
Trial primary completion date: Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL (clinicaltrials.gov) - Dec 14, 2018
P2/3, N=660, Recruiting, Sponsor: Universit
Trial primary completion date: Dec 2019 --> Mar 2020 Trial primary completion date: Sep 2018 --> Mar 2019
- |||| Rituxan (rituximab) / Roche
Trial primary completion date: Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Dec 14, 2018
P3, N=570, Active, not recruiting, Sponsor: Celgene
Trial primary completion date: Sep 2018 --> Mar 2019 Trial primary completion date: Dec 2018 --> Mar 2019
- | Lorbrena (lorlatinib) / Pfizer, Azedra (iobenguane I 131) / Lantheus
Trial completion date, Trial primary completion date: Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (clinicaltrials.gov) - Dec 14, 2018
P3, N=774, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Dec 2018 --> Mar 2019 Trial completion date: Mar 2022 --> Jun 2026 | Trial primary completion date: Mar 2022 --> Jun 2026
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: DLBCL Cell of Origin: What Role Should It Play in Care Today? (Pubmed Central) - Dec 13, 2018
Numerous studies have investigated novel agents in DLBCL with respect to GCB and ABC (or non-GCB) subtypes, but R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) remains the standard of care for most patients. Here we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL.
- ||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (clinicaltrials.gov) - Dec 13, 2018
P2, N=200, Recruiting, Sponsor: St. Jude Children's Research Hospital
Here we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL. Not yet recruiting --> Recruiting
- | Votrient (pazopanib) / Novartis, Nplate (romiplostim) / Amgen, Kyowa Hakko Kirin
Clinical, Journal: Management of disseminated intravascular coagulation in a patient with hepatic angiosarcoma: A case report. (Pubmed Central) - Dec 12, 2018
Not yet recruiting --> Recruiting Laboratory measurement of prothrombin fragment 1.2, a byproduct of prothrombin conversion to thrombin, proved to be a useful way to monitor this patient's DIC over time.
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination: Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer (clinicaltrials.gov) - Dec 12, 2018
P2, N=15, Terminated, Sponsor: University of Nebraska
Laboratory measurement of prothrombin fragment 1.2, a byproduct of prothrombin conversion to thrombin, proved to be a useful way to monitor this patient's DIC over time. N=26 --> 15 | Active, not recruiting --> Terminated; drug toxicity
- | INGN 225 / Lumos Pharma
Trial completion, Trial completion date: Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer (clinicaltrials.gov) - Dec 12, 2018
P1/2, N=24, Completed, Sponsor: University of Nebraska
N=26 --> 15 | Active, not recruiting --> Terminated; drug toxicity Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> Jan 2018
- | Avastin (bevacizumab) / Roche
Trial completion date: Bevacizumab/Doxorubicin/Radiation for Sarcoma (clinicaltrials.gov) - Dec 12, 2018
P1, N=14, Active, not recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> Jan 2018 Trial completion date: Jan 2019 --> Jan 2020
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin (clinicaltrials.gov) - Dec 10, 2018
P=N/A, N=20, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Jan 2019 --> Jan 2020 Trial completion date: Sep 2018 --> Jun 2019 | Trial primary completion date: Sep 2018 --> Jun 2019
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, MRI: Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin (clinicaltrials.gov) - Dec 10, 2018
P=N/A, N=13, Completed, Sponsor: University of Nebraska
Trial completion date: Sep 2018 --> Jun 2019 | Trial primary completion date: Sep 2018 --> Jun 2019 Active, not recruiting --> Completed
- | doxorubicin hydrochloride / Generic mfg.
Journal: Functional Peptide Nanofibers with Unique Tumor Targeting and Enzyme-Induced Local Retention Properties. (Pubmed Central) - Dec 8, 2018
Inside a tumor, GSH-NFP can structurally transform into ten times larger interfibril networks, serving as in situ depot that promotes weeks-long local retention. This nanofiber, which can further be designed to release the active pharmacophores within a tumor microenvironment, displays a superior therapeutic efficacy for inhibiting disease progression and improving the survival of animals bearing triple-negative breast cancer tumors compared to free drug and liposome formulation of the drug, in addition to a favorable toxicity profile.
- | veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 7, 2018
P1, N=90, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
This nanofiber, which can further be designed to release the active pharmacophores within a tumor microenvironment, displays a superior therapeutic efficacy for inhibiting disease progression and improving the survival of animals bearing triple-negative breast cancer tumors compared to free drug and liposome formulation of the drug, in addition to a favorable toxicity profile. Trial primary completion date: Dec 2018 --> Jun 2019
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial primary completion date, Metastases: AEWS1221: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (clinicaltrials.gov) - Dec 7, 2018
P3, N=330, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Jun 2019 Trial primary completion date: Dec 2018 --> Dec 2020
- | Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
Trial completion date, Metastases: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 6, 2018
P1b, N=99, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2018 --> Dec 2020 Trial completion date: Jan 2027 --> Jan 2026
- | New P3 trial, Head-to-Head, Metastases: Randomized phase 3 clinical trial for patients with metastasized childhood renal tumour (EUDRACT) - Dec 4, 2018
P3, N=406, , Sponsor: Gesellschaft f
- ||| Matulane (procarbazine hydrochloride) / Leadiant Biosci
Enrollment closed, Enrollment change: Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 4, 2018
P2, N=7, Active, not recruiting, Sponsor: AIDS Malignancy Consortium
Trial completion date: Jan 2027 --> Jan 2026 Recruiting --> Active, not recruiting | N=90 --> 7
- || Yescarta (axicabtagene ciloleucel) / Gilead
Trial completion date, Trial primary completion date: ZUMA-1: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 4, 2018
P1/2, N=250, Recruiting, Sponsor: Kite, A Gilead Company
Recruiting --> Active, not recruiting | N=90 --> 7 Trial primary completion date: Aug 2018 --> May 2020 | Trial completion date: Mar 2032 --> Oct 2034
- | Opdivo (nivolumab) / BMS, Rituxan (rituximab) / Roche
Enrollment open, Combination therapy: NCI-2018-01666: Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Dec 4, 2018
P1/2, N=30, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Aug 2018 --> May 2020 | Trial completion date: Mar 2032 --> Oct 2034 Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs (clinicaltrials.gov) - Nov 30, 2018
P1/2, N=30, Recruiting, Sponsor: Chinese PLA General Hospital
Not yet recruiting --> Recruiting Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Jun 2018 --> Mar 2019
- | Journal: Acute lymphoblastic leukaemia with osteolytic bone lesions: diagnostic dilemma. (Pubmed Central) - Nov 29, 2018
Findings on flow cytometry were consistent with B-lymphoblastic leukaemia. He was subsequently started on hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin and dexamethasone) induction chemotherapy.
- | Review, Journal: Predicting and Preventing Anthracycline-Related Cardiotoxicity. (Pubmed Central) - Nov 29, 2018
Studies are currently under way to test risk-reducing strategies. There remains a critical need to identify patients with childhood cancer at diagnosis (i.e., prior to anthracycline exposure) such that noncardiotoxic therapies can be contemplated.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: BrUOG 308: Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. (clinicaltrials.gov) - Nov 29, 2018
P2, N=30, Recruiting, Sponsor: William Sikov MD
There remains a critical need to identify patients with childhood cancer at diagnosis (i.e., prior to anthracycline exposure) such that noncardiotoxic therapies can be contemplated. Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Feb 2019
- | Rituxan (rituximab) / Roche
New P2 trial: A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Nov 29, 2018
P2, N=40, Not yet recruiting, Sponsor: University of Rochester
- | Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / Ono Pharma, BMS
New P3 trial, Checkpoint inhibition, Metastases: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (clinicaltrials.gov) - Nov 28, 2018
P3, N=200, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial: Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (clinicaltrials.gov) - Nov 28, 2018
P2, N=125, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- | Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial completion, Combination therapy: A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 27, 2018
P3, N=410, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jul 2018 --> Feb 2019 Active, not recruiting --> Completed